BERG, DoD Using AI Platform to Ready Diagnostic Test for Prostate Cancer
CPDR is a comprehensive research program to study prostate cancer and prostate disease.
CPDR is a comprehensive research program to study prostate cancer and prostate disease.
test
Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Aenean commodo ligula eget dolor. Aenean massa. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Donec quam felis, ultricies nec, pellentesque eu, pretium quis, sem.
Nulla consequat massa quis enim. Donec pede justo, fringilla vel, aliquet nec, vulputate eget, arcu. In enim justo, rhoncus ut, imperdiet a, venenatis vitae, justo. Nullam dictum felis eu pede mollis pretium. Integer tincidunt. Cras dapibus. Vivamus elementum semper nisi. Aenean vulputate eleifend tellus. Aenean leo ligula, porttitor eu, consequat vitae, eleifend ac, enim.
With big data and advanced analytics progressing from fad to frontier status, Pharm Exec examines the readiness of the biopharma industry to take advantage of this promise. Can new digital health tools be harnessed to help advance new treatment approaches and aid decision-making?
BD (Becton, Dickinson and Company) a leader in medical technology, will use BERG‘s artificial intelligence platform to improve patient health by minimizing challenges associated with medication adherence for patients. The partnership will leverage BD’s healthcare IT expertise and BERG’s AI platform to develop a medication adherence algorithm that will help healthcare workers identify certain patient populations that are at the highest risk for nonadherence post-discharge.
Non-obvious correlations to disease management unraveled by Bayesian artificial intelligence analyses of CMS data
Highlights
• Data-driven Bayesian networks based analysis has been performed on health care data.
• Summarized, healthcare provider level data was used for this analysis.
• Novel hypothesis linking diagnosis codes was proposed based on findings from Bayesian networks approach.
• Potential mechanisms were explored to explain novel hypothesis.
• This paper demonstrates the ability of artificial intelligence methods to advance medical research.
Read More
BBC “Talking Business” Host Aaron Heslehurst interviews BERG CEO Niven Narain. In addition to discussing how artificial intelligence can improve the drug-development process, Narain talks about BERG’s new collaboration with AstraZeneca.